NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $1,257,657.38 in Stock

Posted by Stanley Muller on Oct 5th, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) insider Johannes Kastelein sold 50,246 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total value of $1,257,657.38. Following the sale, the insider directly owned 69,302 shares of the company’s stock, valued at $1,734,629.06. This trade represents a 42.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

On Monday, August 24th, Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.91, for a total value of $3,363,750.00.

NewAmsterdam Pharma Stock Performance

NAMS opened at $23.20 on Monday. NewAmsterdam Pharma Company N.V. has a 12-month low of $21.02 and a 12-month high of $42.21. The firm has a 50 day moving average of $25.56 and a two-hundred day moving average of $30.23. The firm has a market capitalization of $2.77 billion, a PE ratio of -10.74 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. As a group, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Royal Bank Of Canada dropped their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. HC Wainwright reiterated a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.73.

View Our Latest Stock Report on NAMS

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. KBC Group NV acquired a new position in NewAmsterdam Pharma in the 1st quarter worth about $37,000. AdvisorNet Financial Inc acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $82,000. Seven Fleet Capital Management LP acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $140,000. PNC Financial Services Group Inc. increased its position in shares of NewAmsterdam Pharma by 147.7% in the first quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company’s stock valued at $292,000 after buying an additional 5,437 shares in the last quarter. Finally, AlphaCentric Advisors LLC increased its position in shares of NewAmsterdam Pharma by 6.7% in the first quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock valued at $469,000 after buying an additional 925 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.